key: cord-1030643-76uusaxh
authors: Fraser, Jacqueline; Mousley, Johanna; Testro, Adam; Smibert, Olivia Catherine; Koshy, Anoop Ninan
title: Clinical Presentation, Treatment and Mortality Rate in Liver Transplant Recipients with COVID-19: A Systematic Review & Quantitative Analysis
date: 2020-07-30
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2020.07.012
sha: c23a5fe66a2acb2f2272f4616294564ef32bebc8
doc_id: 1030643
cord_uid: 76uusaxh

Abstract Liver transplant(LT) recipients may be at increased risk of adverse outcomes with coronavirus disease 2019(COVID-19) infection due to chronic immunosuppression and associated comorbidities. There is a paucity of literature describing clinical presentation, treatments and outcomes in LT recipients with COVID-19. A systematic search was performed for articles published up to June 15, 2020, revealing 223 LT recipients with COVID-19 in 15 studies. Patients most commonly presented with fever(66.7%), dyspnea(34.0%), diarrhea(28.4%). 77.7% required hospitalization, 24% had mild disease, 40% had moderate, and 36% had severe disease. Immunosuppression was modified in 32.8% of recipients. Case fatality rate was 19.3%. Dyspnea on presentation, diabetes mellitus and age ≥60 years were significantly associated with increased mortality(p≤0.01) with a trend to higher mortality rate observed in those with hypertension, and those receiving steroids at the time of COVID-19 diagnosis. The median time from symptoms to death was 11.5 days(2-45). In conclusion, LT recipients with SARS-CoV-2 are overrepresented with regards to severe disease and hospitalizations. Older LT patients with diabetes mellitus or hypertension, on maintenance steroids, with a diagnosis of COVID-19 describing breathlessness should be aggressively monitored for signs of deterioration due to risk of mortality.

Immunosuppression was modified in 32.8% of recipients. Case fatality rate was 19 .3%. Dyspnea on presentation, diabetes mellitus and age ≥60 years were significantly associated with increased mortality(p≤0.01) with a trend to higher mortality rate observed in those with hypertension, and those receiving steroids at the time of COVID-19 diagnosis. The median time from symptoms to death was 11.5 days . In conclusion, LT recipients with SARS-CoV-2 are overrepresented with regards to severe disease and hospitalizations. Older LT patients with diabetes mellitus or hypertension, on maintenance steroids, with a diagnosis of COVID-19 describing breathlessness should be aggressively monitored for signs of deterioration due to risk of mortality.

The clinical presentation of COVID-19 cases and the case fatality rate has varied significantly between both patient subgroups and countries 1 . Various predictors of disease severity have been identified including age, cardiovascular disease, cancer, chronic kidney disease and diabetes [2] [3] [4] [5] [6] [7] . However, data on solid organ transplant recipients has been limited to case reports and series [2] [3] [4] [5] [6] [7] [8] . The case fatality rate from COVID-19 ranges widely from 1 to 7.2% although the rate appears to be much higher for recipients of solid organ transplant recipients 9, 10 .

The clinical course of COVID-19 in liver transplant recipients is variable with biologically plausible reasons to favor both a reduced or intensified immune suppression strategy based on the stage of infection 11 . Further complicating transplant associated complications is the prevalence of cardiovascular risk in transplant recipients including hypertension and metabolic syndrome -both of which confer increased risk for COVID-19 associated mortality 3, 4, 6 . Collating and analyzing rapidly emerging data is vital to identify modifiable risk factors to optimize standardized management. We conducted a systematic review to consolidate current literature on clinical presentation, treatment and outcomes in liver transplant recipients with COVID-19.

A literature search was performed through the EMBASE, PubMed and Web of Science databases up to June 15, 2020. Keywords using Medical Subject Heading (MeSH), where available and Emtree Index terms were developed from main subject headings of "COVID-19", "coronavirinae" and "liver transplantation". The search was limited to articles in English. Reference lists of reviewed articles were screened to identify further relevant studies. The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 12 .

Studies were included if they reported outcomes in liver transplant recipients with confirmed diagnosis of COVID-19 defined as detection of SARS-CoV-2 RNA on a specimen from the respiratory tract from a symptomatic patient. Studies that did not delineate liver transplantation patients from a cohort of solid organ transplantation recipients, multi-organ transplants and in-vitro/animal studies were excluded. Studies reporting the same case were consolidated into one data entry.

Two investigators (J.F. and J.M.) independently searched and extracted relevant articles, of which were subsequently verified by the senior investigator (A.N.K.) with discrepancies resolved by consensus. Data was entered onto detailed forms and included: study design and characteristics, sample size, patient demographics, interval following transplantation, duration of symptoms prior to diagnosis, baseline immunosuppression, severity of disease, treatment administered and mortality.

Patients were stratified into mild, moderate or severe, based on a published classification of COVID-19 severity 11 Quality of data was anticipated to be variable as we predicted the majority of study designs to be case reports or case series.

The primary objective was to characterize the presenting features of COVID-19 in liver transplant recipients and the case-fatality rate. Secondary objectives were to assess for clinical risk predictors of mortality and the management of baseline immunosuppression strategies with COVID-19 disease severity.

Descriptive statistics were presented as absolute and relative frequencies for categorical variables. Comparisons between 2 groups were performed with the χ2 test for categorical data and the Student t-test or Mann-Whitney U test as appropriate for continuous data. A p-value p<0.05 was considered statistically significant. Statistical analysis was performed using Stata 13/MP (StataCorp, College Station, TX). Denominators for baseline characteristics and mortality data varied due to differences in data reporting across studies. (Table 1) .

The initial search yielded 238 studies. We eliminated 218 studies after initial screening. Fifteen studies with a total of 223 patients were included in the final analysis. Details of the literature search are reported in Figure 1 . These included four multicenter registry studies 9, 13-15 , five single-centre case series 10, [16] [17] [18] [19] and five case reports [20] [21] [22] [23] [24] [25] . Studies included reports from Italy, Spain, France, the United States and China.

Among the 223 patients included, 67.8% were over 60 years old and 69.3% were male. The mean age of patients was 59.5 ± 11 years. Of cases that reported on transmission, SARS-CoV-2 was community acquired in 35% of cases, nosocomially acquired in 5% and unclear or not reported in the remaining. The majority (85.2%) experienced infection ≥2 years post transplantation, with only six 13, 19, 20, 22, 23 patients diagnosed within the first month post-transplant. One case was thought to represent a potential donor derived infection with the recipient developing symptoms on Day 2 post-transplant 13, 20 . Clinical characteristics of patients are summarized in Table 1 . Advanced age (>60 years) and diabetes mellitus were significantly associated with mortality (p<0.001 and p=0.01, respectively). Hypertension, body mass index (BMI) ≥25 kg/m 2 , and an immune suppression regimen inclusive of steroids at the time of COVID-19 presentation demonstrated a trend towards increased mortality (Table 1) .

The majority of patients (77.7%) were hospitalized during the course of illness with the remainder of cases either managed in the outpatient setting, or the hospitalization status was not documented. Duration of symptoms prior to presentation was incompletely reported, although the majority underwent testing for SARS-CoV-2 within 7 days of symptom onset. Utilizing the classifications proposed by Siddiqi et al. 11 data on disease severity was available in 76 patients. Of these, 64% of patients had mild-moderate disease and 36% had severe disease. The most common presenting symptoms were fever (67.1%), dyspnea (34.3%), and diarrhea (28.6%) ( Table 1) . Liver function tests (LFTs) were only described in case reports which limited quantification and pooling of data. Data pertaining to thoracic imaging were reported in 42.5% of cases. Of these, 94% demonstrated radiological evidence of COVID-19 on either chest X-ray or chest computed tomography (CT).

Baseline immune suppression regimen was detailed in 52.0% (116/223) of recipients ( Table 1) and was subsequently augmented in 17.0% (38/223) of cases. Of these.

there was either a reduction or cessation of anti-metabolite in 76.3% (29/38) Table 2) . Details of therapies including antivirals, steroids, immunotherapy and antibiotics against survival outcome are summarized in Table 2 .

Overall, 43 (19.3%) patients died due to complications of COVID-19 9, 10, 13-15, 18, 19, 24 .

The median duration of time of symptoms to death in hospital was 11.2 days (2-45 days). Older age, age ≥60 years and diabetes mellitus were significantly associated with increased mortality (p≤0.01). Hypertension and an immune suppression regimen inclusive of steroids at the time of COVID-19 presentation demonstrated a trend towards increased mortality (Table 1) . Liver transplant recipients presenting with dyspnea were at a significantly higher risk of subsequent COVID-19 related mortality (p<0.001). Of the 43 patients that died, all but three were >60 years of age with multiple comorbidities, and all but five were ≥1 year post liver transplant.

Multiple case series support the concept that recipients of solid organ transplant present with more severe COVID-19 disease, are more likely to require hospitalization and have a higher mortality rate from COVID-19 compared to their non-transplant counterparts 10, 27, 28 . This systematic review and quantitative analysis indicates a high mortality rate among liver transplant patients with COVID-19 compared to published reports in the general population 7, 29 . Importantly, we found that when recipients of liver transplant with COVID-19 present with dyspnea, a history of diabetes mellitus and are age ≥60 years, they are at an increased risk of mortality (p≤0.01). These risk factors for subsequent deterioration should serve as critical markers for any clinical teams evaluating recipients of liver transplant with COVID-19 to initiate aggressive monitoring for signs of deterioration.

Liver transplant recipients with COVID-19 experience more severe disease (36%) compared with ~6% reported in the general patient population 30, 31 . The hospitalization rate in this liver transplant cohort was 77.7% which is in contrast to rates of age-adjusted hospitalization in non-transplant recipients aged 20-29 from 1.1% up to 18.4% in those greater than 80 years old 32 . This may be accounted for the older age of the liver transplant cohort (mean = 59.6 years). The observed case fatality rate in our liver transplant cohort with COVID-19 was 19.3%, similar to that seen in thoracic transplant recipients 28 . Whilst this may partly be accountable for due to their older age (mean age = 59.6 years). However, this remains substantially higher that even the 8% mortality rate in an all-comer patient population aged 70-79 29 . This is substantially higher than the mean case-fatality rate of approximately 1-4% in the general population 32, 33 . Given the likelihood of severe disease in this Older (>60 years) recipients of liver transplant presenting with a diagnosis of COVID-19 are associated with a three-fold greater risk of COVID-19 related mortality compared to their younger counterparts age < 60. Older age is a well described risk factor for both severe disease and in-hospital mortality in COVID-19 [2] [3] [4] [5] . A diagnosis of diabetes mellitus at presentation with COVID-19 is also associated with a statistically significant two-fold greater risk of mortality in liver transplant recipients which is consistent with prior reports in non-transplant patients 3, 4 . Diabetes is a well described risk factor for mortality in infections and in the context of COVID-19 has been associated with a more than doubled risk of ICU admission and tripled risk of death in hospitalized COVID-19 patients in meta-analysis 45, 46 

transplant recipients and in the non-immune suppressed, but it is more likely to present with concurrent diarrheal symptoms. Older patients with dyspnea and diabetes mellitus are at a higher risk for mortality and in these patients more intensive monitoring for deterioration should be undertaken as case fatality reaches nearly 23%. There is currently insufficient data to guide optimal immune suppression and COVID-19 directed therapeutic strategies. mToR inhibitor (%) 9.9 6.2 10.9 0.58 BMI = body mass index; mToR = mammalian target of rapamycin. ^Data from Pereira et al. 9 with 'severe disease -defined as ICU admission, intubation or death', were presumed deceased in this analysis. (n = 4) *Data from Belli et al 15 reported overall outcomes, and did not stratify comorbidities, symptoms on presentation and immunosuppression used based on mortality. Denominators used are included in supplementary table 6. Pereira et al. 9 (n=1)

Tocilizumab (IL-6 Antagonist) IVIg = Intravenous Immunoglobulin. ^ Four patients recorded by Pereira et al. 9 as having 'severe disease -defined as ICU admission, intubation or death', were assumed deceased.

Coronavirus Resource Center: Mortality Analyses

Johns Hopkins Institutions; c2020 [updated

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet

Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Critical Care. 2020/03

Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory medicine

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19)

COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter

COVID-19 in solid organ transplant recipients: a single-center case series from Spain

COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

The impact of the COVID-19 outbreak on Liver Transplantation programmes in Northern Italy

Determining risk factors for mortality in liver transplant patients with COVID-19. The lancet Gastroenterology & hepatology

COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry

Health status of liver transplanted patients during the coronavirus outbreak in italy: a large single center experience from milan. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

The facts during the third epidemic

COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

COVID-19 in Liver Transplant Recipients: An Initial Experience from the U

COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation. Archives of pathology & laboratory medicine

Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States

Perioperative Presentation of COVID-19 Disease in a Liver Transplant Recipient

Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients

Fatal outcome in a liver transplant recipient with COVID-19

Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient

Faecal-oral transmission of SARS-COV-2: practical implications

Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia

Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Chinese Center for Disease Control and Prevention

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Estimates of the severity of coronavirus disease 2019: a model-based analysis. The Lancet Infectious Diseases

Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva: World Health Organisation; c2020

Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: A descriptive survey report

A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Clinical Best Practice Advice For Hepatology And Liver Transplant Providers During The Covid-19 Pandemic: Aasld Expert Panel Consensus Statement

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

Expression of SARS-CoV-2 Entry Molecules ACE2 and TMPRSS2 in the Gut of Patients With IBD. Inflammatory bowel diseases

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine

Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study

Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome

Prediction of Perioperative Cardiovascular Events in Liver Transplantation

Suppression of coronavirus replication by cyclophilin inhibitors

Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development

Cyclosporin A inhibits the replication of diverse coronaviruses. The Journal of general virology

Fernandez-Ruiz et al. 10 (n=1)Administered day 1 post symptom onsetFernandez-Ruiz et al. 10 (n=3)